Clinical Trial Search

Primary: Percentage of Participants With 'Pain' or 'no Pain' as Measured by the Numeric Pain Rating Scale — 30; 49; 70; 51 percentage of participants — p=0.053

Primary: Chemotherapy-induced Peripheral Neuropathy (CIPN) Symptoms — 32.32; 33.37 score on a scale — p=0.199

Primary: The Average Pain Severity in the Brief Pain Inventory-Short Form(BPI-SF) — 3.10; 3.10; 1.72; 3.50 score on a scale

Primary: Change in Chemotherapy-induced Peripheral Neuropathy (CIPN) From Baseline — 147.95; 135.82; 167.96; 148.45 percentage of change in CIPN

Primary: Change in Mechanical Visual Analog Scale (mVAS) Using Quantitative Sensory Pain Testing (QSPT) — 5.14; -2.00; 1.25; 6.76 Millimeters

Primary: Relative Change in % pO2 — 12.3; 19; 24; 25.3 change in % oxygenation

Primary: Change in Spontaneous Pain Intensity as a Function of Baseline MPT — -0.0179; -0.0172 Pearson correlation coefficient

Primary: Chemotherapy-induced Peripheral Neuropathy — 21 participants

Primary: Mean Neuropathy Severity Score (FACT-GOG-Ntx Total Score Assessment) — 20.8; 16.7; 9.9; 13.2 units on a scale

Primary: Change in Average Pain From Week 1 to Week 5, as Measured by the BPI-SF Average Pain Severity Item — 1.06; 0.34 units on a scale — p=0.003

Primary: Neurotoxicity Assessment at Baseline — 8.5; 7.3; 5.23; 4.58 units on a scale

Primary: Area Under the Curve (AUC) EORTC CIPN20 Sensory Neuropathy Subscale Adjusting for Baseline — -1.4; -4.4 Average(subscale value*assessment) — p=0.26

Primary: Number of Participants That Complete ≥ 8 EA Treatments of a 10-treatment EA Program — 18 Participants

Primary: Number of Participants Who Achieve at Least a 50% Reduction in Their Primary Problematic Symptom (Either Pain or Tingling) From Baseline on Day 14 — 10; 5 Participants…

Primary: Change in Pain as Measured by the Modified Brief Pain Index at 28 Days — -0.5; -1.06 units on a scale

Primary: Prevention of Peripheral Neuropathy During Taxane Chemotherapy — 7.28 score on a scale

Primary: Change in Average Daily Pain Score as Measured Using a Pain Intensity Rating (NRS) — -0.3; -0.5 units on a scale — p=0.56

Primary: Change in the Sensory Neuropathic Pain Score as Measured by the European Organization of Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire…

Primary: Change in 0 - 10 Numerical Rating Scale of Worst Pain Intensity Scores at 8 Weeks — -0.94; 0 units on a scale — p=<0.05

Primary: Number of Adverse Events (Phase Ib) — 10; 2; 2; 1 Number of Events

Primary: Percentage of Patients Who Have at Least a 50% Reduction (i.e., Success) in at Least 1 of the First 12 Chemotherapy Induced Peripheral Neuropathy (CIPN) Measurement…

Primary: Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) — 41; 30; 25 Participants

Primary: Paclitaxel/Carboplatin (PC) Induced Peripheral Neuropathy as Assessed by EORTC QLQ-CIPN20 (European Organization for Research and Treatment of Cancer (EORTC), Quality of…

Primary: Change in Severity of Chemotherapy-induced Peripheral Neuropathy (CIPN) From Baseline to 3 Months — 5.9; 9.1; 1.9; 5.7 units on a scale

Primary: Change in Pain Score — 2.4 units on a scale

Primary: Change in Subjective Measurement of Chemotherapy-induced Peripheral Neuropathy — 27.32; 27.94 score on a scale

Primary: Area Under the Curve (AUC) Per Assessment (aAUCpa) of Average Pain (Item 3 on the Daily Post-Paclitaxel Questionnaire) — 96.0; 84.3 scores on a scale — p=0.0186

Primary: Change in Average Daily Peripheral Neuropathy Intensity Score From Baseline to Week 6 in Patients Treated With Amitriptyline and Ketamine Hydrochloride vs Placebo…

Primary: Aδ:C Fiber Detection Threshold Ratio — 2.04; 1.57 ratio — p=0.05

Primary: Percentage of Patients With Chemotherapy-induced Sensory Peripheral Neuropathy ≥ Grade 2 — 34; 29 percentage of participants — p=0.43